Argá Medtech today announced positive findings from a first-in-human study of its Coherent Sine-Burst Electroporation (CSE) system. Lausanne, Switzerland–based Argá’s BURST-AF study evaluates the CSE pulsed field ablation (PFA) system. It looks at the treatment of paroxysmal and persistent AFib. It demonstrated 94% overall lesion durability, … [Read more...] about Argá Medtech data supports single-catheter PFA system
Pulsed Field Ablation
Johnson & Johnson MedTech has encouraging Omnypulse results, more data backs Varipulse
Johnson & Johnson MedTech [WtwhTicker symbol="JNJ"](NYSE: JNJ)[/WtwhTicker] today announced 12-month pilot data from a study of its investigational Omnypulse platform for AFib. The Omnypulse platform features the Omnypulse catheter and the Trupulse generator. The company offers the catheter as a large-tip, 12 mm device with Carto 3 mapping … [Read more...] about Johnson & Johnson MedTech has encouraging Omnypulse results, more data backs Varipulse
Abbott studies support pulsed field ablation, dual ablation catheters
Abbott (NYSE: ABT) today announced new clinical data supporting its minimally invasive therapies for treating AFib. Results included 12-month findings supporting the Volt pulsed field ablation (PFA) system and positive outcomes with the TactiFlex Duo Ablation Catheter, Sensor Enabled (SE). Volt provides a single-catheter PFA approach to … [Read more...] about Abbott studies support pulsed field ablation, dual ablation catheters
Field Medical reports positive first-in-human pulsed field ablation data
Field Medical announced the presentation of clinical data from the first-in-human study of its FieldForce pulsed field ablation (PFA) system. The Cardiff-by-the-Sea, California-based company shared findings from the Field PULSE study at the 31st Annual International AF Symposium 2026 in Boston. Field PULSE evaluates a novel, high-voltage, … [Read more...] about Field Medical reports positive first-in-human pulsed field ablation data
Volta reports positive outcomes for AI platform in AFib ablation
Volta Medical today announced results from a clinical trial supporting its AI solution for spatio-temporal dispersion mapping. Results from the RESTART trial, published in Heart Rhythm, demonstrated positive outcomes for patients with recurrent AFib and isolated pulmonary veins who underwent ablation using Volta’s AI solution. The company … [Read more...] about Volta reports positive outcomes for AI platform in AFib ablation
Medtronic wins CE mark for Affera Sphere-360 PFA catheter, reports first U.S. IDE cases
Medtronic (NYSE: MDT) announced two new milestones for its Affera Sphere-360 catheter for pulsed field ablation (PFA) procedures. First, the medtech giant received CE mark approval for the first-of-its-kind, all-in-one mapping and single-shot PFA catheter. It also completed the first cases for the paroxysmal AFib treatment system in the Horizon … [Read more...] about Medtronic wins CE mark for Affera Sphere-360 PFA catheter, reports first U.S. IDE cases
Abbott picks up CE mark for TactiFlex dual-energy ablation catheter
Abbott (NYSE:ABT) Abbott (NYSE: ABT)+ announced today that it received CE mark for its TactiFlex Duo Ablation Catheter, Sensor-Enabled, to treat AFib. Following approval, the company also reported the first commercial cases using the catheter in Europe, completed this week. Dr. Isabel Deisenhofer, head of the department of Electrophysiology at … [Read more...] about Abbott picks up CE mark for TactiFlex dual-energy ablation catheter
Boston Scientific wins FDA nod for Farapoint PFA catheter
A Boston Scientific (NYSE:BSX) executive said on social media that the company received FDA approval for its Farapoint pulsed field ablation (PFA) catheter. SVP and President of Electrophysiology, Nick Spadea-Anello, posted on LinkedIn to congratulate the company for receiving FDA approval for Farapoint. He noted that the approval "closely … [Read more...] about Boston Scientific wins FDA nod for Farapoint PFA catheter
Luma Vision, CardioFocus complete 4D-guided AFib ablation procedures in clinical study
Luma Vision announced that it completed 15 AFib ablation procedures as part of a clinical study in collaboration with CardioFocus. Dublin, Ireland-based Luma Vision said the study aims to, in part, evaluate the ability of its Verafeye 4D navigation and imaging platform. The company designed Verafeye to guide catheter ablation therapy. That … [Read more...] about Luma Vision, CardioFocus complete 4D-guided AFib ablation procedures in clinical study
Stereotaxis MAGiC cardiac ablation catheter wins FDA approval
Stereotaxis (NYSE:STXS) has won FDA approval for its robotically navigated MAGiC ablation catheter, offering a minimally invasive option for patients who otherwise might not be eligible for cardiac ablation to treat complex and critical heart rhythm disorders. MAGiC is short for "magnetic interventional ablation catheter," an abbreviation … [Read more...] about Stereotaxis MAGiC cardiac ablation catheter wins FDA approval










